How Has Edwards Lifesciences Stock Fared in the Last Month?


Dec. 6 2018, Updated 1:50 p.m. ET

Price performance

After witnessing strong gains from $115.41 on January 4, 2018, to a high of $174.10 on September 28, 2018, Edwards Lifesciences (EW) stock slid to $139.22 on October 29. The stock managed to steadily recover to $148.22 on November 21, 2018, and has further added to these gains in December to reach its current $157.3 levels.

Article continues below advertisement

Financial snapshot

Edwards Lifesciences’ revenue grew by 8.12% from $838.5 million in the third quarter of 2017 to $906.6 million in the third quarter of 2018. The company’s revenue in the fourth quarter of 2018 is expected at $978.48 million. Its gross margins expanded from 74.04% in the third quarter of 2017 to 75.50% in the third quarter of 2018. Further for fiscal 2018 and 2019, Edwards Lifesciences’ gross margins are expected at 74.83% and 75.35%, respectively.

From $622.1 million in fiscal 2017, the company’s net income is expected to grow to $981.33 million in fiscal 2018 and $1.09 billion in fiscal 2019.

Analysts’ recommendations

In December 2018, of the total 23 analysts covering Edwards Lifesciences, 13 analysts have given the stock a “buy” or a higher rating, eight analysts have given it a “hold” rating, and two analysts have given Edwards Lifesciences stock a “sell,” or a lower rating. The mean rating for Edwards Lifesciences is 2.35, and its target price is $163, implying an upside potential of 3.6% over its closing price of $157.35 on December 4, 2018.

In the next part, we’ll explore the price performance of Hologic.


More From Market Realist